1. Home
  2. PRLD vs SRV Comparison

PRLD vs SRV Comparison

Compare PRLD & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

N/A

Current Price

$3.23

Market Cap

260.2M

Sector

Health Care

ML Signal

N/A

Logo NXG Cushing Midstream Energy Fund of Beneficial Interest

SRV

NXG Cushing Midstream Energy Fund of Beneficial Interest

SELL

Current Price

$30.48

Market Cap

225.7M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
PRLD
SRV
Founded
2016
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
260.2M
225.7M
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
PRLD
SRV
Price
$3.23
$30.48
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
★ $8.80
N/A
AVG Volume (30 Days)
★ 243.3K
76.7K
Earning Date
11-16-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 23.21
N/A
EPS
N/A
★ N/A
Revenue
★ $12,140,000.00
N/A
Revenue This Year
$74.34
N/A
Revenue Next Year
$85.56
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 73.43
N/A
52 Week Low
$1.30
$32.52
52 Week High
$6.83
$51.54

Technical Indicators

Market Signals
Indicator
PRLD
SRV
Relative Strength Index (RSI) 34.61 24.75
Support Level $2.69 N/A
Resistance Level $3.32 $50.22
Average True Range (ATR) 0.29 1.56
MACD -0.04 -0.34
Stochastic Oscillator 2.53 0.83

Price Performance

Historical Comparison
PRLD
SRV

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest

NXG Cushing Midstream Energy Fund is a non-diversified, closed-end investment company. Its investment objective is to obtain a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in a portfolio of midstream energy investments.

Share on Social Networks: